Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension of subcutaneous efgartigimod PH20 in adults with primary immune thrombocytopenia
MOH_2021-11-10_010389Phase 3Not yet recruiting
- Sponsor
- argenx
- Start
- Jul 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efgartigimod alfa + hyaluronidase-qvfc in immune thrombocytopenia (ITP), sponsored by argenx. Primary endpoint: Not specified. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
efgartigimod alfa + hyaluronidase-qvfc
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on MOH_2021-11-10_010389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-10_010389.